Tenth Circuit: Mylan’s EpiPen rebates not anticompetitive

Sanofi’s claims that Mylan illegally monopolised the market for EpiPens through exclusionary contracts and anticompetitive rebates with insurers and pharmacy benefit managers lack evidence of consumer harm, a federal appeals court has held.

Unlock unlimited access to all Global Competition Review content